|
gptkbp:instanceOf
|
gptkb:drug
VMAT2 inhibitor
|
|
gptkbp:affects
|
dopamine
norepinephrine
serotonin
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N07XX06
|
|
gptkbp:availableOn
|
tablets
|
|
gptkbp:brand
|
gptkb:Xenazine
|
|
gptkbp:CASNumber
|
58-46-8
|
|
gptkbp:chemicalClass
|
benzoquinolizine derivative
|
|
gptkbp:color
|
white to slightly yellow crystalline powder
|
|
gptkbp:contraindication
|
hepatic impairment
active suicidal ideation
untreated depression
|
|
gptkbp:discoveredBy
|
Reserpine derivatives
|
|
gptkbp:eliminationHalfLife
|
5-8 hours
|
|
gptkbp:firstDescribed
|
1950s
|
|
gptkbp:hasMolecularFormula
|
C19H27NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tetrabenazine
|
|
gptkbp:interactsWith
|
gptkb:monoamine_oxidase_inhibitors
gptkb:reserpine
antidepressants
|
|
gptkbp:KEGGID
|
D05913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits vesicular monoamine transporter 2 (VMAT2)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children under 18
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Lundbeck
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
5457
5257
DB04844
|
|
gptkbp:riskFactor
|
QT prolongation
extrapyramidal symptoms
neuroleptic malignant syndrome
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
insomnia
drowsiness
parkinsonism
akathisia
|
|
gptkbp:solubility
|
sparingly soluble in water
|
|
gptkbp:synonym
|
gptkb:Nitoman
gptkb:Tetrabenazinum
|
|
gptkbp:UNII
|
EC2ZZ3B9JB
|
|
gptkbp:usedFor
|
treatment of Huntington's disease
treatment of chorea
|
|
gptkbp:bfsParent
|
gptkb:Austedo
|
|
gptkbp:bfsLayer
|
6
|